WATCHLONGEVITY

Sunday, June 21, 2026

STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
DEVELOPING
Importance
62
Trust
76
Urgency
65
CLINICAL TRIAL✓ 2 outlets

STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential

Pfizer showed new details from a midstage trial of its obesity drug berobenatide, which the company bought from Metsera. The drug appears to work when given once a month instead of more often.

Analysis

Pfizer's once-a-month obesity drug shows promise in mid-stage testing. A monthly shot could be easier for patients than weekly options.

  • Pfizer showed new details from a midstage trial of berobenatide
  • Pfizer bought berobenatide from Metsera
  • Drug appears to work when given once a month
$PFE
berobenatidePfizerMetsera
STAT News — Pharma14d
Read
Importance
45
Trust
71
Urgency
30
COMMERCIAL

GLP-1 Market to Reach $180 Billion by 2035 at 8.7% CAGR | Novo Nordisk, Eli Lilly, Pfizer Among Key Players - openPR.com

Analysis

A market report says GLP-1 drug sales could hit $180 billion by 2035. That points to years of strong growth for Novo and Lilly.

  • GLP-1 market projected to reach $180 billion by 2035
  • Forecast assumes 8.7% compound annual growth rate
  • Novo Nordisk, Eli Lilly, and Pfizer named as key players
$NVO$LLY$PFE
glp1Novo NordiskEli LillyPfizer
Novo Nordisk News1mo
Read
Importance
62
Trust
71
Urgency
30
COMMERCIAL

Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act - BioSpace

Eli Lilly's CEO made critical comments about rivals AbbVie and Pfizer in the race to develop amylin drugs for weight loss. Amylin is a hormone that works differently than current GLP-1 weight-loss medications.

Analysis

Lilly's CEO is talking up its lead in amylin drugs, the next wave of weight-loss shots. Pfizer and AbbVie are also chasing this market.

  • Lilly CEO made critical comments about AbbVie and Pfizer amylin programs
  • Race centers on amylin drugs as the next step beyond GLP-1 weight-loss meds
$LLY$PFE
amylinEli LillyAbbViePfizer
BioSpace1mo
Read
BREAKING
Importance
78
Trust
71
Urgency
95
CLINICAL TRIAL

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial - MSN

Pfizer tested an obesity injection that works once a month in a mid-stage trial and says early results look good. The company is exploring this drug as another option for treating weight gain.

Analysis

Pfizer is back in the obesity race with a once-a-month shot. If it works, patients get fewer injections than weekly drugs from Novo and Lilly.

  • Pfizer reported mid-stage trial results for an obesity injection
  • The drug is dosed once a month
  • Pfizer says early results look promising
$PFE$LLY$NVO
Pfizer
Pfizer Press Releases1mo
Read
DEVELOPING
Importance
88
Trust
71
Urgency
65
DEAL

Pfizer matches Novo bid for obesity biotech Metsera as takeover battle rages - FT - MSN

Pfizer matched Novo Nordisk's offer to buy Metsera, a biotech company working on obesity drugs, as the two companies compete to acquire it. The bidding war shows how much pharmaceutical companies want to add new weight-loss treatments to their pipelines.

Analysis

Pfizer and Novo are fighting to buy Metsera. The winner gets new obesity drugs to challenge Lilly and grow in the booming weight-loss market.

  • Pfizer matched Novo Nordisk's offer to buy obesity biotech Metsera
  • Bidding war underway between Pfizer and Novo for Metsera
$PFE$NVO$MTSR
PfizerNovo NordiskMetsera
Pfizer Press Releases1mo
Read
DEVELOPING
Importance
60
Trust
80
Urgency
65
COMMERCIAL✓ 4 outlets

Pfizer GLP-1 weight loss drug available for pre-order in China - Reuters

Pfizer's GLP-1 weight-loss drug is now available for pre-order in China. This marks the company's entry into the growing market for these medications in the country.

Analysis

Pfizer is pushing into China's huge weight-loss drug market. This puts it up against Novo and Lilly, who already sell similar shots there.

  • Pfizer's GLP-1 weight-loss drug is open for pre-order in China
  • Move marks Pfizer's entry into China's GLP-1 market
$PFE
GLP-1 weight-loss drugPfizer
Reuters Health1mo
Read